Sirnaomics Ltd (2257)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 27 Oct 2026
Key indicators
| Last close | HKD 4.195 |
|---|---|
| 52-week range | 3.550 – 11.710 |
| Return, 1 month / 3 months | +10.4% / +4.9% |
| Return, 1 year / 3 years | −63.3% / −91.3% |
| Trend | Below its 200-day average |
| RSI (14) | 63 |
| Volatility (1 year) | 65.2% |
| Worst drawdown (1 year) | -71.0% |
| Average daily value traded | 0.19M HKD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sirnaomics is a biopharmaceutical company that develops ribonucleic acid interference medicines, often called RNAi therapeutics. Its work centres on small interfering RNA drug candidates designed to silence specific genes involved in disease, with programmes aimed at cancers and fibrotic conditions. The company carries out research and clinical development and is based in Hong Kong, with additional operations in the United States and mainland China. Its customers and partners are mainly in the medical and pharmaceutical research field.
On this site Sirnaomics Ltd appears as a stock on the Hong Kong Stock Exchange (Hong Kong), code 2257, with prices in Hong Kong dollars (HKD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sirnaomics Ltd (2257) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 4.195 on 27 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 2,162 of 2,619 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 63.3% and over the last three months it rose 4.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 18 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -25.4% | ||
| From 52-week high | -63.3% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 4.9% | ||
| 6-month return | -40.7% | ||
| 12-month return, skipping the last month | -66.8% | ||
| Stability (higher is calmer) | 28 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 65.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -71.0% | ||
| Liquidity | 44 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.19M HKD | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.8% |
|---|---|
| 1 month | +10.4% |
| 3 months | +4.9% |
| 6 months | −40.7% |
| 1 year | −63.3% |
| 3 years | −91.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 3.888 / 5.626 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.218 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.